Brief: Axcella Announces Highly Promising Results From Phase 2a Placebo Controlled Clinical Trial For Long COVID
02/08/2022 11:12
Aug 2 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA ANNOUNCES HIGHLY PROMISING RESULTS FROM PHASE 2A
PLACEBO
CONTROLLED CLINICAL TRIAL FOR LONG COVID
* AXCELLA-NO EMERGENT ADVERSE EVENTS (AES) OR SERIOUS
ADVERSE
EVENTS (SAES) OCCURRED
Source text for Eikon: ID:nBw9vkKXla
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment